Basal cell carcinoma natural history: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(45 intermediate revisions by 9 users not shown)
Line 1: Line 1:
__NOTOC__
{{Basal cell carcinoma}}
{{Basal cell carcinoma}}
{{CMG}}
{{CMG}} {{AE}}{{M.N}} Saarah T. Alkhairy, M.D.


==Overview==
==Overview==
It is a slow-growing [[Local|locally]] [[invasive]] [[lesion]] with an unlikely risk of [[metastasis]]. Most [[patients]] are often [[asymptomatic]]. The major [[complication]] is its recurrence and involvement of surrounding structures. With appropriate treatment, the [[prognosis]] is usually excellent.
==Natural History==
*[[Patients]] with basal cell carcinoma are often [[asymptomatic]]<ref name="pmid14525881">{{cite journal |vauthors=Wong CS, Strange RC, Lear JT |title=Basal cell carcinoma |journal=BMJ |volume=327 |issue=7418 |pages=794–8 |date=October 2003 |pmid=14525881 |pmc=214105 |doi=10.1136/bmj.327.7418.794 |url=}}</ref>
*They often report a slowly enlarging [[lesion]] which does not [[Healing|heal]] and [[Bleed|bleeds]] when [[Trauma|traumatized]]
*It is [[Local|locally]] [[invasive]] and destructive so the name [[Rodent ulcer|'''rodent cancer''']]
*The overall risk of [[metastases]] is estimated to be less than 0.1%
*The risk of [[invasion]] and recurrence is based on size, duration, [[Location parameter|location]] and subtype (sclerodermiform/morpheaform and micronodular [[clinical]] variants have a higher risk)
*Even without a recurrence, a [[Personal, Social and Health Education|personal]] [[History and Physical examination|history]] of basal cell carcinoma increases the risk of [[Development|developing]] all types of [[skin cancers]]
==Complications==
*The main [[complication]] of basal cell carcinoma is recurrence.<ref name="WortsmanVergara2015">{{cite journal|last1=Wortsman|first1=X.|last2=Vergara|first2=P.|last3=Castro|first3=A.|last4=Saavedra|first4=D.|last5=Bobadilla|first5=F.|last6=Sazunic|first6=I.|last7=Zemelman|first7=V.|last8=Wortsman|first8=J.|title=Ultrasound as predictor of histologic subtypes linked to recurrence in basal cell carcinoma of the skin|journal=Journal of the European Academy of Dermatology and Venereology|volume=29|issue=4|year=2015|pages=702–707|issn=09269959|doi=10.1111/jdv.12660}}</ref><ref name="pmid22560426">{{cite journal |vauthors=Jebodhsingh KN, Calafati J, Farrokhyar F, Harvey JT |title=Recurrence rates of basal cell carcinoma of the periocular skin: what to do with patients who have positive margins after resection |journal=Can. J. Ophthalmol. |volume=47 |issue=2 |pages=181–4 |date=April 2012 |pmid=22560426 |doi=10.1016/j.jcjo.2012.01.024 |url=}}</ref>
*The following are the factors associated with increased risk of basal cell carcinoma recurrence:
**[[Location parameter|Location]] and size
***>/= 6 mm in [[diameter]] in high-risk areas (eg, central [[face]], [[nose]], [[lips]], [[eyelids]], [[eyebrows]], periorbital [[skin]], [[chin]], [[mandible]], [[ears]], preauricular and postauricular areas, [[temples]], [[hands]], [[feet]])
***10 mm in [[diameter]] in other areas of the [[head]] and [[neck]]
***20 mm in [[diameter]] in all other areas (excluding [[hands]] and [[feet]])
**Aggressive [[Pathological|pathologic]] variants
***Morpheaform, sclerosing, or mixed infiltrative
***Micronodular
***Basosquamous
**[[Lesions]] in sites of prior [[radiation therapy]] (RT)
**[[Lesions]] with poorly defined borders
**[[Lesions]] in [[immunocompromised]] [[patients]]
**Perineural [[invasion]]


==Prognosis==
==Prognosis==
Although basal cell carcinoma rarely [[metastasis|metastasizes]], it grows locally with invasion and destruction of local tissues, without stopping. The cancer can impinge on vital structures and result in loss of extension or loss of function or rarely [[death]]. The vast majority of cases can be successfully treated before serious complications occur. The recurrence rate for the above treatment options ranges from 50% to 1% or less.
*[[Prognosis]] of basal cell carcinoma is usually excellent.<ref name="Czarnecki1998">{{cite journal|last1=Czarnecki|first1=D.|title=The prognosis of patients with basal and squamous cell carcinoma of the skin|journal=International Journal of Dermatology|volume=37|issue=9|year=1998|pages=656–658|issn=00119059|doi=10.1046/j.1365-4362.1998.00559.x}}</ref><ref name="pmid26449265">{{cite journal |vauthors=Correia de Sá TR, Silva R, Lopes JM |title=Basal cell carcinoma of the skin (part 2): diagnosis, prognosis and management |journal=Future Oncol |volume=11 |issue=22 |pages=3023–38 |date=November 2015 |pmid=26449265 |doi=10.2217/fon.15.245 |url=}}</ref>
 
*These [[lesions]] are typically slow growing, and [[metastatic]] [[disease]] is a very [[rare]] event.  
In choosing the therapy, one must weigh the benefit gained from the morbidity of the procedure. As most basal cell carcinomas are slow growing, and not deadly; the health and age of the patient must be considered. Although difficult to discuss, radiation therapy, topical chemotherapy, or no treatment at all should be considered in ill or frail individuals in difficult to excise tumor of no immediate harm to the individual.  While methods with the highest cure rate should be considered for young and healthy individuals with long life expectancy.  It is here that one should seriously consider the cure rate of [[Mohs surgery]] vs. standard excision by a plastic surgeon vs. radiation therapy.
*Basal cell carcinoma will cause considerable [[disfigurement]] by [[Local|locally]] destroying [[skin]], [[cartilage]], and even [[bone]].
*Recurrence is a issue with basal cell carcinoma.
*Approximately 50% of recurrences are apparent within the first two years.


==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[pl:Rak podstawnokomórkowy skóry]]
[[pt:Carcinoma basocelular]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
 
[[Category:Up-To-Date]]
[[Category:Needs content]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Dermatology]]
[[Category:Surgery]]

Latest revision as of 14:36, 11 March 2019

Basal cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Basal Cell Carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Basal cell carcinoma natural history On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Basal cell carcinoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Basal cell carcinoma natural history

CDC on Basal cell carcinoma natural history

Basal cell carcinoma natural history in the news

Blogs on Basal cell carcinoma natural history

Directions to Hospitals Treating Basal cell carcinoma

Risk calculators and risk factors for Basal cell carcinoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2] Saarah T. Alkhairy, M.D.

Overview

It is a slow-growing locally invasive lesion with an unlikely risk of metastasis. Most patients are often asymptomatic. The major complication is its recurrence and involvement of surrounding structures. With appropriate treatment, the prognosis is usually excellent.

Natural History

Complications

Prognosis

References

  1. Wong CS, Strange RC, Lear JT (October 2003). "Basal cell carcinoma". BMJ. 327 (7418): 794–8. doi:10.1136/bmj.327.7418.794. PMC 214105. PMID 14525881.
  2. Wortsman, X.; Vergara, P.; Castro, A.; Saavedra, D.; Bobadilla, F.; Sazunic, I.; Zemelman, V.; Wortsman, J. (2015). "Ultrasound as predictor of histologic subtypes linked to recurrence in basal cell carcinoma of the skin". Journal of the European Academy of Dermatology and Venereology. 29 (4): 702–707. doi:10.1111/jdv.12660. ISSN 0926-9959.
  3. Jebodhsingh KN, Calafati J, Farrokhyar F, Harvey JT (April 2012). "Recurrence rates of basal cell carcinoma of the periocular skin: what to do with patients who have positive margins after resection". Can. J. Ophthalmol. 47 (2): 181–4. doi:10.1016/j.jcjo.2012.01.024. PMID 22560426.
  4. Czarnecki, D. (1998). "The prognosis of patients with basal and squamous cell carcinoma of the skin". International Journal of Dermatology. 37 (9): 656–658. doi:10.1046/j.1365-4362.1998.00559.x. ISSN 0011-9059.
  5. Correia de Sá TR, Silva R, Lopes JM (November 2015). "Basal cell carcinoma of the skin (part 2): diagnosis, prognosis and management". Future Oncol. 11 (22): 3023–38. doi:10.2217/fon.15.245. PMID 26449265.


Template:WikiDoc Sources